What Daxor Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 7 |
| Sells | 0 | 0 |
| Total trades | 1 | 11 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 11 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Jefferies John | Chief Medical Officer | Aug 28 | Grant / award · A | +2,451 | — | — | 26,008 |
| Feldschuh Jonathan Adam | Chief Scientific Officer | Jun 23 | Grant / award · A | +25,000 | — | — | 78,908 |
| Michel Robert J | Chief Financial Officer | Jun 23 | Grant / award · A | +12,000 | — | — | 33,050 |
| Feldschuh Michael Richard | Chief Executive Officer | Jun 23 | Grant / award · A | +30,000 | — | — | 243,694 |
| Feldschuh Michael Richard | Chief Executive Officer | Apr 08 | Open-market buy · P | +1,000 | $9.07 | +$9.07K | 213,694 |
| Michel Robert J | Chief Financial Officer | Mar 31 | Open-market buy · P | +1,000 | $9.90 | +$9.9K | 21,050 |
| Jefferies John | Chief Medical Officer | Mar 20 | Open-market buy · P | +2,285 | — | — | 23,557 |
| Jefferies John | Chief Medical Officer | Mar 20 | Open-market buy · P | +3,656 | — | — | 21,272 |
| Michel Robert J | Chief Financial Officer | Dec 09 | Open-market buy · P | +3,000 | — | — | 20,050 |
| Feldschuh Jonathan Adam | Chief Scientific Officer | Dec 09 | Open-market buy · P | +18,000 | — | — | 53,908 |
| Jefferies John | Chief Medical Officer | Nov 12 | Open-market buy · P | +2,344 | — | — | 17,616 |
| Feldschuh Michael Richard | Chief Executive Officer | Apr 04 | Open-market buy · P | +2,063 | $7.89 | +$16.3K | 212,694 |
| Michel Robert J | Chief Financial Officer | Mar 10 | Open-market buy · P | +1,000 | $8.00 | +$8K | 17,050 |
| Feldschuh Jonathan Adam | Chief Scientific Officer | Dec 06 | Open-market buy · P | +32,000 | — | — | 35,908 |
| Feldschuh Michael Richard | Chief Executive Officer | Dec 06 | Open-market buy · P | +45,000 | — | — | 207,492 |
| Michel Robert J | Chief Financial Officer | Mar 27 | Open-market buy · P | +750 | $8.70 | +$6.53K | 11,300 |
| Feldschuh Michael Richard | Chief Executive Office | Mar 26 | Open-market buy · P | +1,000 | $8.13 | +$8.13K | 210,631 |
| Feldschuh Michael Richard | Chief Executive Officer | Mar 19 | Open-market buy · P | +647 | $8.15 | +$5.27K | 209,631 |
| Feldschuh Michael Richard | Chief Executive Officer | Mar 10 | Open-market buy · P | +1,492 | $7.72 | +$11.5K | 208,984 |
| Feuer Edward | Director | Mar 04 | Open-market buy · P | +1,000 | $7.21 | +$7.21K | 1,000 |
Loading...